Becaplermin News
Cardium Acquires Excellarate Product Candidate for Chronic Diabetic Ulcers and Related Technology and Assets From Tissue Repair Company
Cardium Therapeutics, Inc. (Bulletin board: CDTP) today announced its acquisition of the wound healing technology and related assets of the Tissue Repair Company (TRC), a privately-held, San Diego-based company focused on the...
Regranex® (Becaplermin) Gel Is Effective Treatment Of Diabetic Neuropathic Foot Ulcers, Study Confirms
Johnson & Johnson Wound Management, a division of ETHICON, INC., today announced the publication of results in a study designed to estimate the effectiveness of recombinant human platelet-derived growth factor (rhPDGF) in actual...
Recent Study Confirms REGRANEX® (Becaplermin) Gel To Be Effective Treatment Of Diabetic Neuropathic Foot Ulcers
Somerville, NJ – Johnson & Johnson Wound Management, a division of ETHICON, INC., today announced the publication of results in a study designed to estimate the effectiveness of recombinant human platelet-derived growth factor...
Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor
The author set forth to further assess the responsiveness of hemangioma ulceration to 0.01% becaplermin gel and to compare its cost to that of conventional modalities.